Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis - PubMed (original) (raw)
Meta-Analysis
. 1999 Aug;80(12):1968-73.
doi: 10.1038/sj.bjc.6690628.
Affiliations
- PMID: 10471047
- PMCID: PMC2363143
- DOI: 10.1038/sj.bjc.6690628
Free PMC article
Meta-Analysis
Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis
P D Pharoah et al. Br J Cancer. 1999 Aug.
Free PMC article
Abstract
Many studies have investigated the association between alterations in the p53 gene and clinical outcome of breast cancer, and most investigators have reported poorer overall and disease-free survival (as indicated by a relative hazard (RH) greater than one) in breast cancer cases with somatic mutations in p53. However, different studies have produced widely differing RH estimates, ranging from no risk (RH = 1) to a relative hazard of 23, and not all of these results have been statistically significant. We have therefore reviewed all the published studies that have investigated the association between somatic mutations in the p53 gene and breast cancer prognosis and used standard techniques of meta-analysis to combine the results of these studies to produce a more precise estimate of the prognostic significance of p53 mutations. Eleven studies investigated overall survival in a total of 2319 unselected cases. The RH estimates from these ranged from 1 to 23.4 with a combined RH estimate of 2.0 (confidence interval 1.7-2.5). Three studies investigated the role of p53 in node-negative patients and in these, the combined estimate of RH was 1.7 (1.2-2.3). For three studies of node-positive breast cancer the combined risk estimate was 2.6 (1.7-3.9). The inclusion of p53 mutation screening in large breast cancer clinical trials seems warranted in the light of these results. Analysis of large numbers of cases matched for stage and therapy will allow definitive clarification of the value of p53 mutational status in prognostication, and possibly choice of therapy.
Similar articles
- Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H, Levesque MA, Clark GM, Diamandis EP. Yu H, et al. Br J Cancer. 1999 Oct;81(3):490-5. doi: 10.1038/sj.bjc.6690720. Br J Cancer. 1999. PMID: 10507775 Free PMC article. - Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC, Gumbs AA, Carbone CJ, Carter D, Glazer PM, Haffty BG. Turner BC, et al. Cancer. 2000 Mar 1;88(5):1091-8. Cancer. 2000. PMID: 10699900 - The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale AL. Olivier M, et al. Clin Cancer Res. 2006 Feb 15;12(4):1157-67. doi: 10.1158/1078-0432.CCR-05-1029. Clin Cancer Res. 2006. PMID: 16489069 - Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients.
Verhoog LC, Berns EM, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ, Klijn JG. Verhoog LC, et al. J Clin Oncol. 2000 Nov 1;18(21 Suppl):119S-24S. J Clin Oncol. 2000. PMID: 11060339 Review. - p53 mutations in breast cancer: incidence and relations to tumor aggressiveness and evolution of the disease.
Bautista S, Theillet C. Bautista S, et al. Pathol Biol (Paris). 1997 Dec;45(10):882-92. Pathol Biol (Paris). 1997. PMID: 9769953 Review.
Cited by
- A phenocopy signature of TP53 loss predicts response to chemotherapy.
Bakhtiar H, Sharifi MN, Helzer KT, Shi Y, Bootsma ML, Shang TA, Chrostek MR, Berg TJ, Carson Callahan S, Carreno V, Blitzer GC, West MT, O'Regan RM, Wisinski KB, Sjöström M, Zhao SG. Bakhtiar H, et al. NPJ Precis Oncol. 2024 Oct 2;8(1):220. doi: 10.1038/s41698-024-00722-7. NPJ Precis Oncol. 2024. PMID: 39358429 Free PMC article. - Somatic Mutations in Latin American Breast Cancer Patients: A Systematic Review and Meta-Analysis.
Martínez-Nava GA, Urbina-Jara LK, Lira-Albarrán S, Gómez HL, Ruiz-García E, Nieto-Coronel MT, Ortiz-Lopez R, Martínez Villalba KN, Muñoz-Sánchez M, Aguilar D, Gómez-Flores-Ramos L, Cabrera-Nieto SA, Mohar A, Cruz-Ramos M. Martínez-Nava GA, et al. Diagnostics (Basel). 2024 Jan 29;14(3):287. doi: 10.3390/diagnostics14030287. Diagnostics (Basel). 2024. PMID: 38337803 Free PMC article. Review. - Classification of HER2-negative breast cancers by ERBB2 copy number alteration status reveals molecular differences associated with chromosome 17 gene aberrations.
Loh JW, Lim AH, Chan JY, Yap YS. Loh JW, et al. Ther Adv Med Oncol. 2023 Oct 31;15:17588359231206259. doi: 10.1177/17588359231206259. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37920257 Free PMC article. - The nuclear factor erythroid 2-related factor 2/p53 axis in breast cancer.
Xia L, Ma W, Afrashteh A, Sajadi MA, Fakheri H, Valilo M. Xia L, et al. Biochem Med (Zagreb). 2023 Oct 15;33(3):030504. doi: 10.11613/BM.2023.030504. Biochem Med (Zagreb). 2023. PMID: 37841775 Free PMC article. Review. - Brain metastasis in breast cancer: focus on genes and signaling pathways involved, blood-brain barrier and treatment strategies.
Chhichholiya Y, Ruthuparna M, Velagaleti H, Munshi A. Chhichholiya Y, et al. Clin Transl Oncol. 2023 May;25(5):1218-1241. doi: 10.1007/s12094-022-03050-z. Epub 2023 Mar 10. Clin Transl Oncol. 2023. PMID: 36897508 Review.
References
- Nat Med. 1995 Oct;1(10):1029-34 - PubMed
- Genes Chromosomes Cancer. 1995 Sep;14(1):71-5 - PubMed
- Eur J Cancer. 1995 Oct;31A(11):1856-61 - PubMed
- Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1093-6 - PubMed
- Int J Cancer. 1996 Apr 22;69(2):135-41 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous